CoChat

Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy

Ng Tang, Derek, Shen, Yu, Sun, Jingjing, Wen, Sijin, Wolchok, Jedd D., Yuan, Jianda, Allison, James P., Sharma, Padmanee · 2013 · Cancer Immunology Research

Published version of a preprint

The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.

Abstract

Pharmacodynamic biomarkers can play an important role in understanding whether a therapeutic agent has "hit its target" to impact biologic function. A pharmacodynamic biomarker for anti-CTLA-4 therapy remains to be elucidated. We previously reported that anti-CTLA-4 therapy increases the frequency of CD4 T cells expressing the inducible costimulator (ICOS) molecule. To determine whether the frequency of ICOS(+) CD4 T cells could be used as a pharmacodynamic biomarker for anti-CTLA-4 therapy, we carried out flow cytometric studies and statistical analyses on data from 56 individuals, which included 10 healthy donors, 36 patients who received anti-CTLA-4 monoclonal antibody (mAb), and 10 patients who received treatment with a different immunomodulatory agent (gp100 DNA vaccine). After treatment with anti-CTLA-4 mAb (ipilimumab; Bristol-Myers Squibb), we detected a statistically significant increase in the frequency of ICOS(+) CD4 T-cells. After two doses of anti-CTLA-4 therapy, the assay was found to have an estimated specificity of 96% [95% confidence interval (CI), 88-100] and sensitivity of 71% (95% CI, 54-85), with positive expression defined as a frequency that is more than the upper bound of 95% CI among baseline samples from all subjects. Our data suggest that an increased frequency of ICOS(+) CD4 T cells measured by flow cytometry can be used as a reproducible pharmacodynamic biomarker to indicate biologic activity in the setting of anti-CTLA-4 therapy, which should enable appropriate immune monitoring to determine whether patients receiving anti-CTLA-4 monotherapy or combination treatment strategies are having an adequate biologic response.

Overview

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-13-0020

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

See all 212

Metadata

Authors
Ng Tang, D., Shen, Y., Sun, J., Wen, S., Wolchok, J. D., Yuan, J., Allison, J. P., & Sharma, P.
Affiliations
  • Authors' Affiliations: 1Departments of Genitourinary Medical Oncology, 2Biostatistics, and 3Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas; 4Department of Biostatistics, West Virginia University Health Science Center, Morgantown, West Virginia; and 5Department of Medicine and 6Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, New York
  • West Virginia University (US)
Corresponding author
Sharma, Padmanee
Venue
Cancer Immunology Research
Published
2013-10-01
Volume
1
Issue
4
Pages
229-234
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2144995154
Cited by
203
References
28
Citations by year
2026: 5 · 2025: 7 · 2024: 11 · 2023: 8 · 2022: 11 · 2021: 24 · 2020: 17 · 2019: 17 · 2018: 21 · 2017: 19 · 2016: 32 · 2015: 20 · 2014: 10 · 2013: 1
FWCI
11.24
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P30CA016672)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
ICOS, CD4+ T cells, pharmacodynamic biomarkers, CTLA-4 blockade, ipilimumab, CTLA-4, immune checkpoint blockade, immune monitoring, cancer immunotherapy
MeSH terms
Ipilimumab, Antibodies, Monoclonal, Flow Cytometry, Humans, Lymphocyte Activation, Melanoma, Sensitivity and Specificity, Biomarkers, CD4-Positive T-Lymphocytes, Randomized Controlled Trials as Topic, Cytokines, Vaccines, DNA, Inducible T-Cell Co-Stimulator Protein, CTLA-4 Antigen, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy. https://app.cochat.ai/papers/10.1158/2326-6066.cir-13-0020
The paper
Ng Tang, D., Shen, Y., Sun, J., Wen, S., Wolchok, J. D., Yuan, J., Allison, J. P., & Sharma, P. (2013). Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-13-0020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.